NCT05781893Completed
Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy
BALCoS - Basel Long COVID Cohort Study and DiLCoS - Digital Long COVID Substudy
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
The Basel Long COVID Cohort Study (BALCoS) is a registry-based cohort study that focuses on the patients' present health status, symptoms, the course of these symptoms, and potential mechanisms involved. The project aims to investigate proposed mechanisms behind Post COVID-19 condition (PCC), including a) autoimmunity, b) chronic inflammation, c) genetics, d) coagulation disorders, and e) psychosocial factors. Patients in the cohort can also join the Digital Long COVID Study (DiLCoS), a single-arm, cohort-based proof-of-feasibility study that is part of the larger BALCoS. DiLCoS is a intervention substudy designed to evaluate whether doing exercises delivered via a smartphone app (referred as digital intervention) can help with PCC. The digital intervention is a 12-week program that includes different kinds of exercises like breathing exercises, relaxation techniques, and tips on managing fatigue and other symptoms. It also teaches patients how to monitor their activities and energy levels, and provides psychological exercises to cope with negative thoughts and pain. Patients in the cohort complete a set of assessments that include the collection of sociodemographic and clinical data, biomarkers, neurocognitive testing, psychometric questionnaires, and measures of physical performance, and provide consent that their data from routine clinical care can be used for the study.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 196 (actual)
- First submitted
- 20 Mar 2023
- Start date
- 20 Apr 2023
- Primary completion date
- 6 May 2026
- Lead sponsor
- University Hospital, Basel, Switzerland
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT05781893
What you commit to
- Study type: Observational
- Participants enrolled: 196
- From 20 Apr 2023 to the primary completion date, 6 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \<18 years
Other
- Lack of consent to participate in the study
- Language barriers (lack of sufficient knowledge of German)
- Lack of general understanding of study procedures
Who the study is looking for
- Patients diagnosed with PCC will be included. PCC will be defined as:
- History of confirmed or suspected SARS CoV-2 infection
- Symptoms usually start within 3 months from the onset of acute SARS CoV-2 infection with symptoms and effects that last for at least 2 months
- Symptoms cannot be explained by an alternative diagnosis
- signed informed consent is required
- Additional Inclusion Criteria for participtation in DiLCoS:
- A smartphone with a compartible-operating system
- Separate signed informed consent is required
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Basel, Department of Psychosomatic Medicine Coordinator of this site? Confirm its status | Basel | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.